Welcome to our dedicated page for Galera Therapeutics news (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on Galera Therapeutics stock.
Galera Therapeutics develops clinical-stage oncology therapeutics and reports corporate updates under the GRTX symbol. Company news has centered on its shift toward anti-cancer therapeutics following the completed acquisition of Nova Pharmaceuticals, including a pan-inhibitor of Nitric Oxide Synthase program studied in advanced breast cancer settings.
Recurring updates also cover Galera’s portfolio and capital structure, including the disposition of its dismutase mimetics assets such as avasopasem and rucosopasem, financing activity, stockholder voting matters, governance actions, and operating and financial results. Earlier company disclosures addressed clinical and regulatory matters for cancer-related product candidates and strategic alternatives for the business.
Galera Therapeutics (GRTX) announced positive findings from a retrospective analysis of Phase 2b trial data for avasopasem manganese (GC4419), a drug aimed at reducing radiation-induced toxicities in cancer treatment. The trial showed a significant reduction in chronic kidney disease incidences among patients who received cisplatin and avasopasem. These results will be presented at the ASCO 2020 Virtual Scientific Program. Additionally, ongoing Phase 3 ROMAN and Phase 1b/2a trials are set to yield further data in the second half of 2020 and 2021, respectively.
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that CEO Mel Sorensen, M.D. will present virtually at the BofA Securities 2020 Health Care Conference on May 12, 2020, at 9:40 a.m. EDT. The presentation will be accessible via a live audio webcast on Galera's Investors page, with an archived version available for 30 days post-event. Galera focuses on developing novel therapeutics to transform cancer radiotherapy, including their lead candidate, avasopasem manganese, currently in Phase 3 trials for reducing radiation-induced severe oral mucositis.